ADMA - ADMA Biologics up in after-hours trading following quarterly top and bottom line beats

Shares of ADMA Biologics (NASDAQ:ADMA) are up 2% in after-hours trading after the company's Q4 2021 results beat on both the top and bottom lines. The company is also guiding full-year 2022 revenue of more than $125M, which would be more than 50% year-over-year growth. ADMA's (ADMA) net loss narrowed ~14% in the quarter to ~$16.6M compared to the prior-year period (-$0.09 per share basic and diluted vs. -$0.20). Total operating expenses increased ~38% compared to Q4 2021 to $16.7M. Revenue of ~$26.4M was an 89% year-over-year increase. The company ended the year with ~$51.1M in cash. Read why Seeking Alpha contributor Jeffrey Himelson says that ADMA is a strong buy.

For further details see:

ADMA Biologics up in after-hours trading following quarterly top and bottom line beats